Evidence map›Paper›PMID 42757160›Full record

ArticleACS omega2026

Identification, Structure-Activity Relationship (SAR), and Biological Evaluation of New Chemical Series as Malaria Parasite

Pedro Martin-Acosta, Abbas H K Al Temimi, Luma Godoy Magalhaes, Juan Salamanca-Viloria, Jose Ignacio Martin Hernando, Ana I Villegas, Virginia Franco Hidalgo, Joel McMillan, Andrew Plater, Mark Anderson and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Pedro Martin-AcostaGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Abbas H K Al TemimiGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Luma Godoy MagalhaesDrug Discovery Unit (DDU), Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee DD1 5EH, U.K.
Juan Salamanca-ViloriaGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Jose Ignacio Martin HernandoGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Ana I VillegasCharles River Laboratories, PTM, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Virginia Franco HidalgoGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Joel McMillanDrug Discovery Unit (DDU), Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee DD1 5EH, U.K.
Andrew PlaterDrug Discovery Unit (DDU), Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee DD1 5EH, U.K.
Mark AndersonDrug Discovery Unit (DDU), Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee DD1 5EH, U.K.
Raquel GabarroGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Felix CalderonGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Maria Santos Martinez-MartinezGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Emiliana D'OriaGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Jair L Siqueira-NetoSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States.
Barbara ForteDrug Discovery Unit (DDU), Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee DD1 5EH, U.K.ORCID https://orcid.org/0000-0003-3986-5880
Esther FernandezGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Elizabeth A WinzelerDepartment of Pediatrics, University of California, San Diego, La Jolla, California 92093, United States.
Ana Lisa ValencianoGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.
Beatriz BaragañaDrug Discovery Unit (DDU), Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee DD1 5EH, U.K.ORCID https://orcid.org/0000-0002-0959-1113
Sonia Moliner-CubelGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.ORCID https://orcid.org/0000-0002-1881-506X
Francisco Javier GamoGlobal Health Medicines R&D, GSK Tres Cantos, Madrid 28760, Spain.ORCID https://orcid.org/0000-0002-1854-2882

Funding

Targeting the Genus Leishmania with Small MoleculesR01AI151639 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BROWN, LAUREN ELAINE, SCHAUS, SCOTT EDWARD · 2021 to 2025
$3.8M
Discovery of long-acting, chemoprotective antimalarial compoundsR01AI152533 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2020 to 2024
$3.5M
Bill & Melinda Gates Foundation INV-026519NIAID NIH HHS R01 AI151639NIAID NIH HHS R01 AI152533Wellcome Trust
6 · The paper itself

Abstract

Despite considerable progress in prevention, treatment, and eradication efforts, malaria continues to impose a significant public health and socioeconomic burden for many countries around the globe. With the effectiveness of current treatment options partially or totally compromised due to resistance, the validation of new targets and the development of new drugs that can reach the demanding standards required for the treatment of this disease represent an urgent and considerable challenge. Herein, we report the evaluation of approximately 48 200-compound library selected from the GSK collection against

Identifiers

PMID42757160
PMCPMC13584588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.